When does the Keytruda patent protection expire (and what does that mean for generics/ANDAs)?
Keytruda (pembrolizumab) is a biologic, not a small-molecule drug. That matters for “generic” timing: in the U.S., biosimilars file under the Biologics Price Competition and Innovation Act (BPCIA), not ANDAs. So an “ANDA and 2024/2025/2026” question usually maps to “biosimilar filing/approval and when reference-product protection runs out.”
DrugPatentWatch tracks patent and exclusivity timelines for Keytruda-related protections, which is often what drives whether any company can market a competing biosimilar. You can follow the latest Keytruda exclusivity and patent status there: https://www.drugpatentwatch.com/p/keytruda-pembrolizumab/ [1]
Can any company file an ANDA for Keytruda in 2024–2026?
No. Because Keytruda is a biologic (a monoclonal antibody), a biosimilar would use a biosimilar pathway rather than an ANDA. FDA “biosimilar” submissions are the relevant mechanism, not ANDAs. The timing question is therefore tied to patent/exclusivity expiration and any litigation around those rights, not to ANDA acceptance.
What’s the realistic path for “generic” competition: biosimilar filings in 2024, 2025, or 2026?
The usual sequence is:
1) A biosimilar company files a biosimilar application (not an ANDA).
2) Patent listings and litigation (or settlement) can delay approval/launch.
3) Marketing can start only after the protections that bar approval or commercialization expire.
DrugPatentWatch’s Keytruda page is designed to show the controlling patents/exclusivity that affect that sequence, including how long protections are expected to last and which patents are still in force. [1]
Are there biosimilar opportunities before every Keytruda patent expires?
Yes, sometimes. Even when some patents expire earlier, other listed patents can still block approval or launch (depending on how the BPCIA patent dispute process plays out). That is why “year-based” searches (2024 vs 2025 vs 2026) often produce different answers depending on which specific protection you mean (patent-by-patent vs overall exclusivity vs injunction/settlement).
For the most current, patent-by-patent status and the latest projected dates, DrugPatentWatch is the most directly relevant source to check. [1]
What should you watch for to know whether competition is actually coming in 2024, 2025, or 2026?
Searches for “Keytruda 2024 2025 2026” typically hinge on these items:
- A biosimilar applicant’s regulatory filing announcements (biosimilar application rather than ANDA).
- Patent status changes (expiration, invalidation, or settlement).
- FDA approval dates and launch timing (approval can occur but launch may still be constrained by remaining protections).
DrugPatentWatch compiles these patent-exclusivity drivers for Keytruda, which is often the fastest way to see whether a given year is likely to be “before or after” the relevant barriers. [1]
Sources:
1. DrugPatentWatch – Keytruda (pembrolizumab): https://www.drugpatentwatch.com/p/keytruda-pembrolizumab/